Literature DB >> 32238365

Caseum: a Niche for Mycobacterium tuberculosis Drug-Tolerant Persisters.

Jansy P Sarathy1, Véronique Dartois2.   

Abstract

Caseum, the central necrotic material of tuberculous lesions, is a reservoir of drug-recalcitrant persisting mycobacteria. Caseum is found in closed nodules and in open cavities connecting with an airway. Several commonly accepted characteristics of caseum were established during the preantibiotic era, when autopsies of deceased tuberculosis (TB) patients were common but methodologies were limited. These pioneering studies generated concepts such as acidic pH, low oxygen tension, and paucity of nutrients being the drivers of nonreplication and persistence in caseum. Here we review widely accepted beliefs about the caseum-specific stress factors thought to trigger the shift of Mycobacterium tuberculosis to drug tolerance. Our current state of knowledge reveals that M. tuberculosis is faced with a lipid-rich diet rather than nutrient deprivation in caseum. Variable caseum pH is seen across lesions, possibly transiently acidic in young lesions but overall near neutral in most mature lesions. Oxygen tension is low in the avascular caseum of closed nodules and high at the cavity surface, and a gradient of decreasing oxygen tension likely forms toward the cavity wall. Since caseum is largely made of infected and necrotized macrophages filled with lipid droplets, the microenvironmental conditions encountered by M. tuberculosis in foamy macrophages and in caseum bear many similarities. While there remain a few knowledge gaps, these findings constitute a solid starting point to develop high-throughput drug discovery assays that combine the right balance of oxygen tension, pH, lipid abundance, and lipid species to model the profound drug tolerance of M. tuberculosis in caseum.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  caseum; foamy macrophages; granuloma; hypoxia; intracellular lipophilic inclusions; necrosis; persistence; phenotypic drug resistance; tuberculosis

Mesh:

Substances:

Year:  2020        PMID: 32238365      PMCID: PMC7117546          DOI: 10.1128/CMR.00159-19

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  146 in total

1.  Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

Authors:  Zahoor Ahmad; Mostafa M Fraig; Gregory P Bisson; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  The Influence of Foodstuffs upon the Respiratory Metabolism and Growth of Human Tubercle Bacilli.

Authors:  R O Loebel; E Shorr; H B Richardson
Journal:  J Bacteriol       Date:  1933-08       Impact factor: 3.490

Review 3.  New insights into the function of granulomas in human tuberculosis.

Authors:  Timo Ulrichs; Stefan H E Kaufmann
Journal:  J Pathol       Date:  2006-01       Impact factor: 7.996

4.  Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.

Authors:  N Mor; B Simon; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

5.  Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.

Authors:  Russell R Kempker; M Tobias Heinrichs; Ketino Nikolaishvili; Irina Sabulua; Nino Bablishvili; Shota Gogishvili; Zaza Avaliani; Nestani Tukvadze; Brent Little; Adam Bernheim; Timothy D Read; Jeannette Guarner; Hartmut Derendorf; Charles A Peloquin; Henry M Blumberg; Sergo Vashakidze
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

6.  Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice.

Authors:  S Aly; K Wagner; C Keller; S Malm; A Malzan; S Brandau; F-C Bange; S Ehlers
Journal:  J Pathol       Date:  2006-11       Impact factor: 7.996

7.  ideR, An essential gene in mycobacterium tuberculosis: role of IdeR in iron-dependent gene expression, iron metabolism, and oxidative stress response.

Authors:  G Marcela Rodriguez; Martin I Voskuil; Benjamin Gold; Gary K Schoolnik; Issar Smith
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

8.  Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.

Authors:  Jean-Philippe Lanoix; Anne J Lenaerts; Eric L Nuermberger
Journal:  Dis Model Mech       Date:  2015-03-30       Impact factor: 5.758

Review 9.  Neutrophils: Innate Effectors of TB Resistance?

Authors:  Elouise E Kroon; Anna K Coussens; Craig Kinnear; Marianna Orlova; Marlo Möller; Allison Seeger; Robert J Wilkinson; Eileen G Hoal; Erwin Schurr
Journal:  Front Immunol       Date:  2018-11-14       Impact factor: 7.561

10.  Storage lipid studies in tuberculosis reveal that foam cell biogenesis is disease-specific.

Authors:  Valentina Guerrini; Brendan Prideaux; Landry Blanc; Natalie Bruiners; Riccardo Arrigucci; Sukhwinder Singh; Hsin Pin Ho-Liang; Hugh Salamon; Pei-Yu Chen; Karim Lakehal; Selvakumar Subbian; Paul O'Brien; Laura E Via; Clifton E Barry; Véronique Dartois; Maria Laura Gennaro
Journal:  PLoS Pathog       Date:  2018-08-30       Impact factor: 6.823

View more
  21 in total

Review 1.  Modulation of the M. tuberculosis cell envelope between replicating and non-replicating persistent bacteria.

Authors:  Haley Stokas; Heather L Rhodes; Georgiana E Purdy
Journal:  Tuberculosis (Edinb)       Date:  2020-10-05       Impact factor: 3.131

2.  Intradermal comparative cervical tuberculin test in the diagnosis of caprine tuberculosis.

Authors:  Carlos Augusto Scacchetti de Almeida; Caio R Dos Santos; Nilson Roberti Benites; Ricardo S Jordão; Érica Chimara; Fernando José Benesi; Sergio S de Azevedo; Márcio Garcia Ribeiro; Sônia Regina Pinheiro
Journal:  Braz J Microbiol       Date:  2021-11-12       Impact factor: 2.476

3.  GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.

Authors:  Eric L Nuermberger; Maria Santos Martínez-Martínez; Olalla Sanz; Beatriz Urones; Jorge Esquivias; Heena Soni; Rokeya Tasneen; Sandeep Tyagi; Si-Yang Li; Paul J Converse; Helena I Boshoff; Gregory T Robertson; Gurdyal S Besra; Katherine A Abrahams; Anna M Upton; Khisimuzi Mdluli; Gary W Boyle; Sam Turner; Nader Fotouhi; Nicholas C Cammack; Juan Miguel Siles; Marta Alonso; Jaime Escribano; Joel Lelievre; Joaquin Rullas-Trincado; Esther Pérez-Herrán; Robert H Bates; Gareth Maher-Edwards; David Barros; Lluís Ballell; Elena Jiménez
Journal:  Antimicrob Agents Chemother       Date:  2022-05-24       Impact factor: 5.938

Review 4.  Types and functions of heterogeneity in mycobacteria.

Authors:  Eun Seon Chung; William C Johnson; Bree B Aldridge
Journal:  Nat Rev Microbiol       Date:  2022-04-01       Impact factor: 78.297

Review 5.  One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics.

Authors:  Hee-Jeong Yang; Decheng Wang; Xin Wen; Danielle M Weiner; Laura E Via
Journal:  Front Cell Infect Microbiol       Date:  2021-03-16       Impact factor: 5.293

6.  Neutrophil Dynamics Affect Mycobacterium tuberculosis Granuloma Outcomes and Dissemination.

Authors:  Caitlin Hult; Joshua T Mattila; Hannah P Gideon; Jennifer J Linderman; Denise E Kirschner
Journal:  Front Immunol       Date:  2021-10-05       Impact factor: 7.561

7.  Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis.

Authors:  Jonah Larkins-Ford; Talia Greenstein; Nhi Van; Yonatan N Degefu; Michaela C Olson; Artem Sokolov; Bree B Aldridge
Journal:  Cell Syst       Date:  2021-08-31       Impact factor: 10.304

Review 8.  Pathogenesis of Human Immunodeficiency Virus-Mycobacterium tuberculosis Co-Infection.

Authors:  Kevin Wong; James Nguyen; Lillie Blair; Marina Banjanin; Bunraj Grewal; Shane Bowman; Hailey Boyd; Grant Gerstner; Hyun Jun Cho; David Panfilov; Cho Ki Tam; Delaney Aguilar; Vishwanath Venketaraman
Journal:  J Clin Med       Date:  2020-11-06       Impact factor: 4.241

9.  Antibiotic tolerance.

Authors:  Lars F Westblade; Jeff Errington; Tobias Dörr
Journal:  PLoS Pathog       Date:  2020-10-15       Impact factor: 6.823

10.  Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832.

Authors:  Gregory T Robertson; Michelle E Ramey; Lisa M Massoudi; Claire L Carter; Matt Zimmerman; Firat Kaya; Barbara G Graham; Veronica Gruppo; Courtney Hastings; Lisa K Woolhiser; Dashick W L Scott; Bryce C Asay; Franceen Eshun-Wilson; Ekaterina Maidj; Brendan K Podell; Joshua J Vásquez; Mike A Lyons; Véronique Dartois; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.